Data on odevixibat for treatment of Alagille syndrome presented at NASPGHAN 2020
Data from recent studies on odevixibat (Albireo Pharma, Inc) for the treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, and Alagille syndrome was presented at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2020 Annual Meeting according to a company press release. Odevixibat is a highly potent, once-daily, non-systemic ileal bile acid transport inhibitor (IBATi).
“Our leading approach to rare cholestatic liver disease research has been underscored this year, therefore, we are very pleased to present new data on odevixibat at NASPGHAN,” said Ron Cooper, President and Chief Executive Officer of Albireo in a press release. “Poster presentations will also include a trial design overview of our global, gold standard approach with the BOLD clinical trial evaluating odevixibat, which is the largest Phase 3 trial in biliary atresia, as well as health economics and outcomes research focused on the burden of disease in PFIC.”
Read the full press release here.
